Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-01-14 Regulatory Filings
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia rapporterar behandling av första patienten med trippelnegativ bröstcancer i TRIFOUR-studien
Regulatory Filings Classification · 95% confidence The document is a press release ("Pressmeddelande") dated January 14, 2022, announcing that the first patient has been treated in the TRIFOUR clinical study for triple-negative breast cancer (TNBC) using the drug nadunolimab. It details the study design, collaboration, and next steps. The text concludes with a standard disclaimer stating that the information is required to be made public under EU market abuse regulation and specifies the release time. This format—a brief announcement of a specific corporate/clinical development event, often released via a press wire—is characteristic of a general regulatory announcement that doesn't fit into the highly specific categories like 10-K, ER, or DIV. Since it is a formal announcement required for market transparency but doesn't fit the definitions for specific financial reports, capital changes, or management changes, the most appropriate fallback category is Regulatory Filings (RNS). The document length (5957 chars) is substantial enough that it is not merely an RPA announcing a report, but the report/announcement itself.
2022-01-14 Swedish
Cantargia tar nästa steg med nadunolimab mot bukspottkörtelcancer i PanCAN:s kliniska fas 2/3-studie Precision Promise?
Legal Proceedings Report Classification · 99% confidence The document is a press release (indicated by "Pressmeddelande") dated January 3, 2022, announcing a significant development regarding the drug nadunolimab. Specifically, it states that Cantargia AB has entered into an agreement for their drug to be included in PanCAN's clinical Phase 2/3 study, Precision Promise℠. This announcement details future regulatory steps (pre-IND application to the FDA in Q2 2022) and clinical trial plans. Since this is an announcement about a clinical trial progression and partnership, it is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). It is a general corporate update concerning clinical development and strategy. Given the options, this type of announcement, which details clinical progress and partnership agreements, most closely aligns with a general corporate/investor update. It is not a specific financing event (CAP), management change (MANG), or dividend notice (DIV). It is a significant corporate announcement, but it is not a formal regulatory filing like a 10-K or a specific report like an IR. Since it is a press release detailing clinical trial progress and strategic partnership, it fits best under the general category of Investor Relations/Corporate News. Among the provided codes, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate general category for a press release detailing clinical trial progression that doesn't fit a more specific category like ER or CT. However, since it is a detailed update on clinical strategy and progress, it could also be considered an Investor Presentation (IP) if it were a slide deck, but as a press release, RNS is the safest fallback for non-standard announcements. Given the context of clinical trial updates, it is a form of investor communication. Since there is no specific 'Clinical Update' code, and it is not a formal report itself, RNS is the best fit as a general regulatory/corporate announcement.
2022-01-03 Swedish
Cantargia advances nadunolimab against pancreatic cancer in the PanCAN Precision Promise[SM] phase 2/3 clinical trial
Regulatory Filings Classification · 95% confidence The document is a press release dated January 3, 2022, announcing that Cantargia AB's drug, nadunolimab, will be included in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM phase 2/3 clinical trial. It details the trial design, endpoints (overall survival), and regulatory steps (Pre-IND submission planned for Q2 2022). This type of announcement, detailing progress in clinical trials and strategic partnerships, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a detailed announcement about clinical strategy and trial advancement, 'Investor Presentation' (IP) is the most fitting category, as it provides substantial information intended for investors regarding future prospects, even though it is formatted as a press release. It is not a formal regulatory filing like 10-K or a short announcement of a report (RPA/RNS).
2022-01-03 English
Cantargia rapporterar uppdaterade lovande överlevnadsdata från CANFOUR-studien med nadunolimab och cellgifter i bukspottkörtelcancer
Earnings Release Classification · 99% confidence The document is a press release ("Pressmeddelande") from Cantargia AB dated December 29, 2021, reporting updated interim survival data from their clinical study CANFOUR regarding the drug nadunolimab in combination with chemotherapy for pancreatic cancer. It details efficacy metrics (median survival, iPFS, 1-year survival) and safety profiles, comparing them to historical control data. This content strongly aligns with an Earnings Release (ER) which typically announces key periodic financial/operational results, or potentially an Interim Report (IR) if it were the full comprehensive report. However, since this is a focused press release announcing clinical trial results and operational updates, and not a comprehensive quarterly financial filing, it fits best under the 'Earnings Release' category (ER) which covers initial announcements of periodical results/highlights, or potentially 'Regulatory Filings' (RNS) if it were purely regulatory disclosure. Given the nature of reporting clinical trial updates which often accompany or precede formal financial reporting periods, and the format being a press release announcing key performance indicators (KPIs) for the drug pipeline, ER is the most appropriate fit among the provided options for a biotech company's operational update release. It is not a full 10-K, AR, or IR, but a highlight announcement. FY 2021
2021-12-29 Swedish
Cantargia reports updated encouraging survival data from CANFOUR trial with nadunolimab and chemotherapy in pancreatic cancer
Legal Proceedings Report Classification · 99% confidence The document is explicitly labeled as a "Press release" and announces "updated encouraging survival data" from a clinical trial (CANFOUR) involving their drug nadunolimab. It provides key efficacy metrics (median survival, iPFS, 1-year survival rate) and quotes the CEO. This format, focusing on timely, high-level results dissemination via a press release, strongly indicates an Earnings Release (ER) or a general announcement. Since it is not a full, comprehensive financial report (like a 10-K or IR), and it is not explicitly announcing the *publication* of a formal report (which would suggest RPA), the best fit among the options for a timely announcement of clinical/operational results is the Earnings Release (ER) category, as clinical trial updates often accompany or substitute for traditional earnings releases in biotech/pharma, or serve a similar function of providing key period performance indicators. Given the context of providing updated data and the structure of a press release, ER is the most appropriate classification, although RNS is a possibility if ER is strictly reserved for financial quarters. However, the content is a major operational update, fitting the spirit of an ER.
2021-12-29 English
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in CANTARGIA AB, explicitly mentioning 'Reason for major shareholding notification' and providing updated share quantities and voting rights percentages that cross a threshold (5%). This structure and content directly align with the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2021-12-22 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.